Log in
Show password
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Dynamic quotes 


Delayed Quote. Delayed Nyse - 09/24 04:10:00 pm
73.61 USD   +0.77%
09/24Health Care Stocks Retreat Friday
09/24Wall Street Tumbles Pre-Bell, Evergrande Risks Resurface
09/24Health Care Stocks Slip Pre-Bell Friday
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Oncosec Medical Incorporated Enters into Clinical Research Cooperation Agreement with Merck to Conduct Global Phase III Study of Interleukin-12 (IL-12) Plasmid DNA Drug TavoÖ in Combination with the Anti-PD-1 Drug Keytruda« (Pembrolizumab) in Advanced Metastatic Melanoma

07/09/2021 EDT

China Grand Pharmaceutical and Healthcare Holdings Limited announced that OncoSec Medical Incorporated (‘OncoSec’) announced that it has entered into clinical research cooperation agreement with Merck to conduct a global phase III study of the interleukin-12 (IL-12) plasmid DNA drug TAVO™ in combination with the anti-PD-1 drug KEYTRUDA® (pembrolizumab) in advanced metastatic melanoma (‘KEYNOTE-C87 Study’). The planned clinical trial will evaluate the overall survival of patients treated with the TAVOTM in combination with KEYTRUDA® versus standard of care in late-stage patients with metastatic melanoma who are refractory to immune checkpoint therapy. Sticking to patients-centered and innovation-driven, the Group continue to expand its strategic planning in anti-tumor field and increase its investment in the world-class innovative products in the fields of radiopharmaceuticals and anti-tumor immunology. Through cooperating with the three global leading anti-tumor pharmaceutical companies which are invested by the Group, including US based OncoSec, Australia based Sirtex Medical Pty Ltd. and Telix Pharmaceuticals Limited, the Group will continue to introduce world-class innovative products for different cancer indications in response to unmet clinical needs and enrich product pipeline and improve supply chain, dedicating itself into building world-leading radiopharmaceuticals platform and anti-tumor immunology platform, and integrating diagnostics and treatment. The Group will continue to adopt the strategy of ‘global expansion and dual-cycle operation’, forming a new pattern of domestic and international cycles that synergize with each other. According to the terms of the Cooperation Agreement, the KEYNOTE-C87 study is planned to be carried out in the United States, Canada, the European Union and Australia, and plans to recruit about 400 patients with stage III or IV unresectable metastatic melanoma who are ineffective for immune checkpoint therapy. The study aims to support the accelerated approval of TAVO™ by the FDA and is also as a pivotal study to support the full licensure of TAVO™ for marketing. TAVO™, the core product of OncoSec, can continuously express IL-12 in tumors and its microenvironment based on the DNA encoding IL-12 to trigger the immune response of the body, enabling the immune system to target and attack tumor cells in order to inhibiting tumor cells growth. Its treatment method for drug-resistant metastatic melanoma was granted Orphan Drug status by the US Food and Drug Administration (FDA) in 2017. At present, TAVO™ has received Fast Track Designation from the FDA. With the development of its clinical combination with KEYTRUDA® or OPDIVO® (nivolumab), TAVO™ is expected to become a potential first-in-class drug in the world for the treatment of metastatic melanoma. The market prospect is very considerable.

ę S&P Capital IQ 2021
All news about MERCK & CO., INC.
09/24Health Care Stocks Retreat Friday
09/24Wall Street Tumbles Pre-Bell, Evergrande Risks Resurface
09/24Health Care Stocks Slip Pre-Bell Friday
09/24MERCK : LYNPARZA« (olaparib) in Combination With Abiraterone Significantly Delayed Disease..
09/24AstraZeneca and Merck Announce Positive Results from the Phase 3 PROpel Trial
09/24ASTRAZENECA : Merck & Co.'s Combination Therapy Benefits Prostate Cancer Patients in Phase..
09/24ASTRAZENECA : Merck & Co.'s Prostate Cancer Drug Extends Lives in Late-Stage Study
09/21MERCK : Thinking about trading options or stock in Draftkings, Merck, ConocoPhillips, Walg..
09/21MERCK : Building Sustainable Value for our Business and Society
09/20MERCK : KEYTRUDA (pembrolizumab) Plus Chemotherapy With or Without Bevacizumab Reduced Ris..
More news
Analyst Recommendations on MERCK & CO., INC.
More recommendations
Financials (USD)
Sales 2021 46 881 M - -
Net income 2021 12 645 M - -
Net Debt 2021 15 254 M - -
P/E ratio 2021 16,1x
Yield 2021 3,52%
Capitalization 186 B 186 B -
EV / Sales 2021 4,30x
EV / Sales 2022 3,89x
Nbr of Employees 73 500
Free-Float 70,7%
Chart MERCK & CO., INC.
Duration : Period :
Merck & Co., Inc. Technical Analysis Chart | MRK | US58933Y1055 | MarketScreener
Technical analysis trends MERCK & CO., INC.
Short TermMid-TermLong Term
Income Statement Evolution
Mean consensus BUY
Number of Analysts 22
Last Close Price 73,61 $
Average target price 93,42 $
Spread / Average Target 26,9%
EPS Revisions
Managers and Directors
Robert M. Davis President, Chief Executive Officer & Director
Caroline A. Litchfield Chief Financial Officer & Executive Vice President
Kenneth C. Frazier Executive Chairman
Sandy Tremps Vice President-R&D IT CIO
Dave Williams Chief Information & Digital Officer
Sector and Competitors
1st jan.Capi. (M$)
MERCK & CO., INC.-10.01%186 334
JOHNSON & JOHNSON4.44%432 675
ROCHE HOLDING AG10.16%321 605
PFIZER, INC.20.05%246 358
NOVO NORDISK A/S50.45%231 485